Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-26T14:52:27.109Z Has data issue: false hasContentIssue false
  • English
  • Français

Gabexate mesilate hastens recovery from vecuronium-induced neuromuscular blockade

Published online by Cambridge University Press:  13 April 2005

H. Hattori ,
Y. Saitoh ,
H. Nakajima ,
N. Sanbe ,
M. Akatu  and
M. Murakawa
H. Hattori
Affiliation:
Fukushima Medical University School of Medicine, Department of Anesthesiology, Fukushima, Japan
Y. Saitoh
Affiliation:
Fukushima Medical University School of Medicine, Department of Anesthesiology, Fukushima, Japan
H. Nakajima
Affiliation:
Fukushima Medical University School of Medicine, Department of Anesthesiology, Fukushima, Japan
N. Sanbe
Affiliation:
Fukushima Medical University School of Medicine, Department of Anesthesiology, Fukushima, Japan
M. Akatu
Affiliation:
Fukushima Medical University School of Medicine, Department of Anesthesiology, Fukushima, Japan
M. Murakawa
Affiliation:
Fukushima Medical University School of Medicine, Department of Anesthesiology, Fukushima, Japan
Get access

Extract

Summary

Background and objective: To test the hypothesis that gabexate mesilate, a protease inihibitor, hastens recovery from neuromuscular blockade, we examined the effect of gabexate mesilate on the recovery of vecuronium-induced neuromuscular blockade in anaesthetized patients in a double-blind, randomized fashion.

Methods: Thirty adult patients were divided into two groups of 15. In the gabexate mesilate group, immediately after administration of vecuronium 0.1 mg kg−1, a continuous infusion of gabexate mesilate was started at a speed of 1.5 mg kg−1 h−1. In the control group, normal saline was administered instead of gabexate mesilate. Times to the return of T1, T2, T3 or T4 (first, second, third and fourth response of train-of-four (TOF)), times to the recovery of T1/control to 0.25 (T25) or 0.5 (T50), recovery of T1/control or TOF ratio (T4/T1) were compared between the two groups.

Results: Times to the returns of T1, T2, T3 and T4 in the gabexate mesilate group were significantly shorter than in the control group (19.4 ± 6.8 vs. 25.7 ± 7.2 min for T1; mean ± SD, P = 0.020). Times to T25 and T50 were significantly shorter in the gabexate mesilate group than in the control group (34.0 ± 9.9 vs. 51.3 ± 10.2 min for T25, P < 0.001). T1/control and TOF ratio in the gabexate mesilate group were significantly higher than in the control group 40–80 min and 40–120 min after administration of vecuronium, respectively (P < 0.05).

Conclusion: Gabexate mesilate hastens recovery from neuromuscular block in anaesthetized patients receiving vecuronium.

Keywords

PHARMACOLOGY, drug interactionsPROTEASE INHIBITORS, gabexate mesilateNEUROMUSCULAR BLOCKING AGENTS, vecuronium, recovery
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 22 , Issue 1 , January 2005 , pp. 20 - 24
Copyright
© 2005 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Harvey AL, Karlsson E. Protease inhibitor homologues from mamba venoms: facilitation of acetylcholine release and interactions with prejunctional blocking toxins. Br J Pharmacol 1982; 77: 153–161.Google Scholar
Mastumoto N, Ohara K, Yoshida N, et al. Protective effects of ulinastatin on hepatic oxygen metabolism during halothane anesthesia in the presence of graded hypoxic hypoxemia. Masui (Jap J Anesthesiol) 1989; 38: 531–539.Google Scholar
Harada N, Okajima K, Kushimoto S. Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation. Crit Care Med 1999; 27: 1958–1964.Google Scholar
Kim YI, Hwang YJ, Song KE, Yun YK, Lee JW, Chun BY. Hepatocyte protection by a protease inhibitor against ischemia/reperfusion injury of human liver. J Am Coll Surg 2002; 195: 41–50.Google Scholar
Chen HM, Hwang TL, Chen MF. The effect of gabexate mesilate on pancreatic and hepatic microcirculation in acute experimental pancreatitis in rats. J Surg Res 1996; 66: 147–153.Google Scholar
Casson WR, Jones RM. Vecuronium induced neuromuscular blockade. The effect of increasing dose on speed of onset. Anaesthesia 1986; 41: 354–357.Google Scholar
Upton RA, Nguyen TL, Miller RD, Castagnoli Jr N. Renal and biliary elimination of vecuronium ORG NC 45 and pancuronium in rats. Anesth Analg 1982; 61: 313–316.Google Scholar
Bencini AF, Scaf AHJ, Agoston S, Houwertjes MC, Kersten UW. Disposition of vecuronium in the cat. Br J Anaesth 1985; 57: 782–788.Google Scholar
Saitoh Y, Fujii Y, Oshima T. The ulinastatin-induced effect on neuromuscular block caused by vecuronium. Anesth Analg 1999; 89: 1565–1569.Google Scholar
Saitoh Y, Kaneda K, Murakawa M. The effect of ulinastatin-pretreatment on vecuronium-induced neuromuscular block in patients with hepatic cirrhosis. Anaesthesia 2002; 57: 218–222.Google Scholar
Viby-Mogensen J, Engbaek J, Eriksson LI, et al. Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiol Scand 1996; 40: 59–74.Google Scholar
Lee GC, Iyengar S, Szenohradszky J, et al. Improving the design of muscle relaxant studies. Stabilization period and tetanic recruitment. Anesthesiology 1997; 87: 459–460.Google Scholar
Ono S, Aosasa S, Mochizuki H. Effects of a protease inhibitor on reduction of surgical stress in esophagectomy. Am J Surg 1999; 177: 78–82.Google Scholar
Smith CE, van Miert MM, Parker CJ, Hunter JM. A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1′R-cis isomer of atracurium, with atracurium besilate in healthy patients. Anaesthesia 1997; 52: 833–841.Google Scholar
De Wolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth 1996; 76: 624–628.Google Scholar
Xue FS, Liao X, Liu JH, et al. Dose-response curve and time-course of effect of vecuronium in male and female patients. Br J Anaesth 1998; 80: 720–724.Google Scholar
Chauvin M, Lebrault C, Duvaldestin P. The neuromuscular blocking effect of vecuronium on the human diaphragm. Anesth Analg 1987; 66: 117–122.Google Scholar
Kopman AF. The relationship of evoked electromyographic and mechanical responses following atracurium in humans. Anesthesiology 1985; 63: 208–211.Google Scholar
Saitoh Y, Kaneda K, Hattori H, Nakajima H, Murakawa M. Monitoring of neuromuscular block after administration of vecuronium in patients with diabetes mellitus. Br J Anaesth 2003; 90: 480–486.Google Scholar
Saitoh Y, Kaneda K, Tokunaga Y, Murakawa M. Infusion of amino acid enriched solution hastens recovery from neuromuscular block caused by vecuronium. Br J Anaesth 2001; 86: 814–821.Google Scholar
Nishijima MK, Takezawa J, Taenaka N, Shimada Y, Yoshiya I. Application of HPLC measurement of plasma concentration of gabexate mesilate. Thromb Res 1983; 31: 279–284.Google Scholar